Trade LCTX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Lineage Cell Therapeutics, Inc. (LCTX) is trading at US$1.01, down 2.43% today as of Oct 9, 13:28 EDT. The company has a market capitalisation of US$273.14M. Over the past 52 weeks, LCTX has traded between US$0.88 and US$2.09. On Syfe you can trade LCTX with $0 commission and add it to your watchlist.
| Previous close | US$1.03 |
|---|---|
| Market cap | US$273.14M |
| 52-week range | US$0.88 – US$2.09 |
| Volume | 2.01M |
| Exchange | US |
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Year: 1992
--Canaccord Genuity Initiates Coverage on Lineage Cell Therapeutics With Buy Rating, $9 PT
Apr 28, 11:38 AM · MT Newswires
Lineage Cell Therapeutics, Inc. (LCTX) stock is trading at US$1.01, -2.43% from the previous close of US$1.03.
The market cap for Lineage Cell Therapeutics, Inc. (LCTX) stock is approximately US$273.14M.
The 52-week high for Lineage Cell Therapeutics, Inc. (LCTX) stock is US$2.09.
The 52-week low for Lineage Cell Therapeutics, Inc. (LCTX) stock is US$0.88.
Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay a dividend.
Stay on top of LCTX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
